at CNBC.com (Feb 28, 2014)
Endologix (ELGX +1.8%) pipeline looks impressive, says Oppenheimer. After meeting with management, the firm says ELGX's growth story remains intact and that abdominal aortic aneurysm market volumes and pricing remain solid. The firm thinks the Street is still underestimating the value of the company's Nelix treatment and reiterates a Buy on the stock.
From other sites
at CNBC.com (Dec 5, 2013)
at MarketWatch.com (May 1, 2012)
at MarketWatch.com (Feb 23, 2011)